Dame Emma Walmsley is stepping down as CEO of pharmaceutical giant GSK after eight transformative years at the helm. She will be succeeded by current Chief Commercial Officer Luke Miels, effective 1 January 2026. Walmsley will remain with the company in an advisory role until the end of September 2026 to support a smooth leadership transition.
Her departure comes at a crucial juncture for both GSK and the broader pharmaceutical industry, which faces mounting global pressure over pricing, regulation, and investment competitiveness. Walmsley described 2026 as a “pivotal year” for GSK, making this the “right moment” for new leadership.
During her tenure, Walmsley led a significant corporate restructuring, most notably the demerger of GSK’s consumer healthcare division, which became Haleon — now a standalone £29 billion business. She also broke barriers as the first woman to lead a major global pharmaceutical firm. Her leadership helped GSK solidify its identity as a focused biopharma innovator, with stronger R&D momentum and a promising pipeline. Her pay package last year exceeded £10 million.
Despite these achievements, the company’s share price performance has been relatively stagnant, trading below peers in the sector. Analysts cite consistent delivery on financial guidance but note single-digit growth rates and investor skepticism around GSK’s long-term targets, including a £40 billion revenue goal by 2031.
Incoming CEO Luke Miels inherits both opportunities and challenges. The pharmaceutical sector is navigating turbulent waters, with the U.S. demanding lower drug prices and increased investment, while some companies are pulling back from the UK. Merck recently scrapped a £1bn research centre, and Eli Lilly criticized the UK as the “worst country in Europe” for drug pricing.
AstraZeneca, another UK-based pharma giant, has also paused investment and plans a direct listing on the New York Stock Exchange — a signal of shifting global dynamics.
Despite these headwinds, GSK has momentum. The firm is on track for five major regulatory approvals this year and delivers over 1 million vaccine doses daily. Recent clarity in the Zantac litigation has also removed a major financial overhang.
Walmsley expressed confidence in Miels, saying, “I know Luke will lead brilliantly to even greater impact for patients.” She also noted her pride in building a stronger GSK and launching Haleon, adding, “Now is the time for new leadership as I begin my own new adventures.”
Shares in GSK rose 3% following the announcement.
